HESTERBIO - Hester Biosciences Ltd Share Price

Pharmaceuticals & Biotechnology

₹1951.60-58.60(-2.92%)

Market Closed as of Aug 8, 2025, 15:30 IST

Select time range

Valuation
Market Cap	1.53 kCr
Price/Earnings (Trailing)	53.22
Price/Sales (Trailing)	4.87
EV/EBITDA	26.72
Price/Free Cashflow	34.93
MarketCap/EBT	43.25
Enterprise Value	1.74 kCr

Fundamentals
Revenue (TTM)	315.03 Cr
Rev. Growth (Yr)	-10.1%
Earnings (TTM)	28.83 Cr
Earnings Growth (Yr)	-75.9%

Profitability
Operating Margin	11%
EBT Margin	11%
Return on Equity	8.82%
Return on Assets	4.41%
Free Cashflow Yield	2.86%

Price to Sales Ratio

Latest reported: 5

Revenue (Last 12 mths)

Latest reported: 315 Cr

Net Income (Last 12 mths)

Latest reported: 29 Cr

Growth & Returns
Price Change 1W	-6.4%
Price Change 1M	-2.6%
Price Change 6M	-17.5%
Price Change 1Y	-41.8%
3Y Cumulative Return	-6.6%
5Y Cumulative Return	6.8%
7Y Cumulative Return	6.4%
10Y Cumulative Return	9.6%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-19 Cr
Cash Flow from Operations (TTM)	64.51 Cr
Cash Flow from Financing (TTM)	-51.72 Cr
Cash & Equivalents	5.59 Cr
Free Cash Flow (TTM)	43.92 Cr
Free Cash Flow/Share (TTM)	51.63

Balance Sheet
Total Assets	653.38 Cr
Total Liabilities	326.73 Cr
Shareholder Equity	326.66 Cr
Current Assets	195.17 Cr
Current Liabilities	125.18 Cr
Net PPE	232.68 Cr
Inventory	70.38 Cr
Goodwill	0.00

Capital Structure & Leverage
Debt Ratio	0.32
Debt/Equity	0.64
Interest Coverage	1.79
Interest/Cashflow Ops	6.08

Dividend & Shareholder Returns
Dividend/Share (TTM)	14
Dividend Yield	0.31%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.00%

Risk & Volatility
Max Drawdown	-25.1%
Drawdown Prob. (30d, 5Y)	34.62%
Risk Level (5Y)	44%

Pros

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Smart Money: Smart money has been increasing their position in the stock.

Profitability: Recent profitability of 9% is a good sign.

Balance Sheet: Strong Balance Sheet.

Cons

Past Returns: Underperforming stock! In past three years, the stock has provided -6.6% return compared to 14.6% by NIFTY 50.

Technicals: SharesGuru indicator is Bearish.

Momentum: Stock is suffering a negative price momentum. Stock is down -2.6% in last 30 days.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	0.31%
Dividend/Share (TTM)	14
Shares Dilution (1Y)	0.00%
Earnings/Share (TTM)	33.89

Financial Health
Current Ratio	1.56
Debt/Equity	0.64

Technical Indicators
RSI (14d)	52.14
RSI (5d)	16.56
RSI (21d)	48.37
MACD Signal	Sell
Stochastic Oscillator Signal	Hold
Grufity Signal	Sell
RSI Signal	Hold
RSI5 Signal	Buy
RSI21 Signal	Hold
SMA 5 Signal	Sell
SMA 10 Signal	Sell
SMA 20 Signal	Sell
SMA 50 Signal	Sell
SMA 100 Signal	Sell

Summary of Latest Earnings Report from Hester Biosciences

Summary of Hester Biosciences's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated:

Q&A Session

Last updated:

Revenue Breakdown

Analysis of Hester Biosciences's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.

Revenue

Last Updated: Jun 30, 2025

Description	Share	Value
Poultry Healthcare	50.1%	42.1 Cr
Animal Healthcare	49.9%	42 Cr
Total		84.1 Cr

Share Holdings

Understand Hester Biosciences ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
Rajiv Dinesh Gandhi	10.47%
Sanjiv Dinesh Gandhi	8.2%
Nina Rajiv Gandhi	8.19%
Shaila Bhupendra Gandhi	5.78%
Ravin Gandhi	4.74%
Bela Gandhi	4.71%
Bhupendra Vithaldas Gandhi	4.69%
Kuntal Hasmukhlal Shah	3.17%
Biolink Healthcare Limited	2.93%
Manish Jain	2.88%
Anup Chandravadan Kapadia	2.68%
Darshna Dinesh Kapadia	1.81%
Vinay Shah	1.28%
Manish Jain (HUF)	1.23%
Manish Prataprai Gandhi	1.18%
Jagrut Prataprai Gandhi	1.18%
Sandeep Shantilal Gala	1.06%
Hester Coatings LLP	0.75%
Hester Diagnostics Private Limited	0.28%
Hetal Sanjiv Gandhi	0.23%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is Hester Biosciences Better than it's peers?

Detailed comparison of Hester Biosciences against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
BAYERCROP	Bayer CropScience	28.48 kCr	4.53 kCr	+10.20%	-4.40%	48.54	6.28	-	-
GODREJAGRO	Godrej Agrovet	16.13 kCr	9.43 kCr	+9.60%	-1.00%	37.54	1.71	-	-
AVANTIFEED	Avanti Feeds	9.93 kCr	5.78 kCr	-1.70%	+3.70%	18.78	1.72	-	-
SEQUENT	Sequent Scientific	4.35 kCr	1.57 kCr	-10.40%	+21.60%	199.91	2.78	-	-

Sector Comparison: HESTERBIO vs Pharmaceuticals & Biotechnology

Comprehensive comparison against sector averages

Comparative Metrics

HESTERBIO metrics compared to Pharmaceuticals

Category	HESTERBIO	Pharmaceuticals
PE	53.22	36.76
PS	4.87	5.31
Growth	-0.1 %	7.5 %

Performance Comparison

HESTERBIO vs Pharmaceuticals (2021 - 2025)

Key Insights

1. HESTERBIO is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 0.1% in Pharmaceuticals.
3. In last one year, the company has had a below average growth that other Pharmaceuticals companies.

Income Statement for Hester Biosciences

Consolidated figures (in Rs. Crores) / View Standalone Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	2%	311	305	266	235	214	183
Other Income	-70.8%	3.92	11	15	14	4.68	6.37
Total Income	0%	315	315	281	249	219	190
Cost of Materials	18.9%	64	54	53	61	39	29
Purchases of stock-in-trade	-46.9%	18	33	30	13	7.97	6.52
Employee Expense	-3.2%	62	64	56	45	39	41
Finance costs	-36.8%	13	20	9.32	4.06	6.6	7.37
Depreciation and Amortization	0%	17	17	21	17	13	13
Other expenses	8.9%	99	91	82	67	57	68
Total Expenses	-2.8%	280	288	246	196	166	148
Profit Before exceptional items and Tax	30.8%	35	27	36	53	53	41
Exceptional items before tax	-	0	0	0	0	-3.32	0
Total profit before tax	30.8%	35	27	36	53	50	41
Current tax	10%	12	11	11	15	17	12
Deferred tax	-163.8%	-1.48	0.06	0.84	-0.77	-1.54	-1.84
Total tax	0%	11	11	12	14	15	10
Total profit (loss) for period	40%	29	21	28	39	35	31
Other comp. income net of taxes	8.7%	0.06	-0.03	1.62	0.82	-1.58	2.05
Total Comprehensive Income	40%	29	21	30	40	33	33
Earnings Per Share, Basic	37.7%	33.89	24.88	32.96	46.41	40.79	36.44
Earnings Per Share, Diluted	37.7%	33.89	24.88	0	46.41	40.79	36.44

Description	(%) Q/Q	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023
Revenue From Operations	30.6%	82	63	84	82	79	67
Other Income	-216.7%	-6.95	7.81	1.84	1.23	4.14	0.99
Total Income	5.7%	75	71	86	83	83	68
Cost of Materials	-6.2%	16	17	16	16	14	13
Purchases of stock-in-trade	-2.4%	4.7	4.79	3.02	5.09	6.41	5.96
Employee Expense	-13.3%	14	16	16	16	16	16
Finance costs	196%	5.62	-3.81	5.89	5.01	6.94	2.19
Depreciation and Amortization	-3.3%	4.18	4.29	4.2	4.13	3.74	3.75
Other expenses	28.6%	28	22	24	25	26	21
Total Expenses	24.1%	73	59	75	74	74	63
Profit Before exceptional items and Tax	-86.9%	2.44	12	11	9.73	9.39	5.2
Total profit before tax	-86.9%	2.44	12	11	9.73	9.39	5.2
Current tax	378.5%	4.11	1.65	3.38	3.08	3.92	1.74
Deferred tax	-321.7%	-1.91	0.31	0.1	0.03	-0.45	0.66
Total tax	25%	2.2	1.96	3.48	3.11	3.47	2.39
Total profit (loss) for period	-94.6%	1.54	11	8.39	7.49	6.39	4.02
Other comp. income net of taxes	14.6%	-0.17	-0.37	0.21	0.39	1.15	-0.23
Total Comprehensive Income	-96.3%	1.37	11	8.6	7.88	7.55	3.79
Earnings Per Share, Basic	-93.4%	1.82	13.41	9.86	8.8	7.52	4.73
Earnings Per Share, Diluted	-93.4%	1.82	13.41	9.86	8.8	7.52	4.73

Standalone figures (in Rs. Crores) / View Consolidated Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	0.4%	286	285	254	219	208	169
Other Income	15.3%	4.76	4.26	5.32	4.66	1.65	2.93
Total Income	0.7%	291	289	259	224	210	172
Cost of Materials	18.8%	39	33	29	35	24	21
Purchases of stock-in-trade	-21.4%	45	57	55	39	25	17
Employee Expense	-3.6%	55	57	48	39	33	37
Finance costs	6.8%	5.37	5.09	6.5	2.47	3.95	5.03
Depreciation and Amortization	-13.7%	8.58	9.78	9.79	9.5	9.63	9.38
Other expenses	7.5%	87	81	71	58	50	57
Total Expenses	-1.6%	249	253	215	171	150	131
Profit Before exceptional items and Tax	13.9%	42	37	44	53	60	41
Exceptional items before tax	-	0	0	0	0	-5.28	0
Total profit before tax	13.9%	42	37	44	53	55	41
Current tax	15.9%	11	9.63	11	14	16	12
Deferred tax	-121.7%	-1.35	-0.06	0.86	-0.51	-1.48	-1.8
Total tax	4.1%	9.92	9.57	12	14	15	10
Total profit (loss) for period	19.2%	32	27	32	40	40	31
Other comp. income net of taxes	-33.3%	-0.36	-0.02	0.11	-0.16	0.21	-0.4
Total Comprehensive Income	15.4%	31	27	32	39	40	31
Earnings Per Share, Basic	17.8%	37.43	31.93	38.018	46.45	46.9	36.7
Earnings Per Share, Diluted	17.8%	37.43	31.93	38.018	46.45	46.9	36.7

Description	(%) Q/Q	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023
Revenue From Operations	22.6%	77	63	74	73	73	66
Other Income	-80%	1.06	1.3	1.35	1.06	1.2	0.98
Total Income	22.2%	78	64	75	75	74	66
Cost of Materials	7.8%	9.02	8.44	11	11	9.17	6.65
Purchases of stock-in-trade	18.2%	14	12	9.26	9.93	14	14
Employee Expense	-15.4%	12	14	14	14	14	14
Finance costs	-57.6%	1.25	1.59	1.4	1.13	1.31	1.37
Depreciation and Amortization	-16.9%	2.03	2.24	2.19	2.12	2.08	2.57
Other expenses	33.3%	25	19	20	23	23	19
Total Expenses	14%	66	58	62	63	64	58
Profit Before exceptional items and Tax	82.1%	11	6.49	12	11	10	8.61
Total profit before tax	82.1%	11	6.49	12	11	10	8.61
Current tax	304.5%	3.67	1.66	3.07	2.87	3.28	1.51
Deferred tax	-362.3%	-1.82	0.39	0.08	0	-0.48	0.63
Total tax	-19%	1.85	2.05	3.14	2.87	2.79	2.14
Total profit (loss) for period	150.9%	9.63	4.44	9.34	8.43	7.43	6.47
Other comp. income net of taxes	-32.7%	-0.34	-0.01	-0.01	-0.01	-0.11	0.03
Total Comprehensive Income	141.7%	9.29	4.43	9.33	8.43	7.32	6.5
Earnings Per Share, Basic	144.8%	11.33	5.22	10.97	9.91	8.74	7.61
Earnings Per Share, Diluted	144.8%	11.33	5.22	10.97	9.91	8.74	7.61

Balance Sheet for Hester Biosciences

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	-64.7%	5.59	14	13	13	13	17
Loans, current	-0.6%	5.76	5.79	5.86	5.83	5.99	6.09
Total current financial assets	-21.6%	106	135	119	137	117	109
Inventories	4.5%	70	67	76	80	85	77
Current tax assets	-	0	0	-	-	0	0
Total current assets	-12.2%	195	222	215	238	228	206
Property, plant and equipment	-0.9%	233	235	239	245	259	255
Capital work-in-progress	3.5%	177	171	168	162	146	110
Non-current investments	-	0	0	0	0	25	23
Total non-current financial assets	81.7%	5.58	3.52	3.79	5.06	30	28
Total non-current assets	2.5%	458	447	448	445	442	418
Total assets	-2.4%	653	669	662	683	670	624
Borrowings, non-current	-14.3%	133	155	182	190	185	190
Total non-current financial liabilities	-14.7%	140	164	190	197	191	197
Provisions, non-current	-5.4%	2.75	2.85	2.53	2.26	1.93	1.41
Total non-current liabilities	-11.5%	202	228	254	260	233	244
Borrowings, current	-12%	74	84	57	77	83	71
Total current financial liabilities	-2.6%	114	117	96	122	130	104
Provisions, current	109.4%	1.03	0.68	0.76	0.66	0.51	0.6
Current tax liabilities	111.2%	4.02	2.43	2.46	2.69	3.4	2.55
Total current liabilities	-1.6%	125	127	106	132	149	109
Total liabilities	-7.9%	327	355	359	391	381	353
Equity share capital	0%	8.51	8.51	8.51	8.51	8.51	8.51
Non controlling interest	0%	12	12	11	9.61	8.82	6.66
Total equity	4.2%	327	314	303	292	289	271
Total equity and liabilities	-2.4%	653	669	662	683	670	624

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	-141.4%	0.54	2.11	2.41	1.63	4.3	1.9
Loans, current	-1.3%	5.7	5.76	5.69	5.67	5.85	6.09
Total current financial assets	-16.4%	108	129	115	131	111	98
Inventories	-3.3%	59	61	69	73	79	71
Current tax assets	-	0	0	0	0	-	0
Total current assets	-12.4%	185	211	204	225	216	188
Property, plant and equipment	-1.9%	105	107	103	104	108	101
Capital work-in-progress	3.5%	177	171	168	162	146	110
Non-current investments	0%	65	65	44	65	65	65
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	3%	70	68	48	70	69	69
Total non-current assets	2.9%	361	351	345	339	330	304
Total assets	-2.9%	546	562	550	564	546	491
Borrowings, non-current	-20.6%	51	64	79	88	83	90
Total non-current financial liabilities	-20.3%	52	65	80	88	84	91
Provisions, non-current	-9.2%	2.38	2.52	2.26	1.98	1.72	1.41
Total non-current liabilities	-12.1%	110	125	139	145	117	122
Borrowings, current	-28.8%	53	74	54	74	81	66
Total current financial liabilities	-16.8%	90	108	94	114	123	90
Provisions, current	81.4%	0.92	0.57	0.67	0.63	0.44	0.34
Current tax liabilities	139.1%	3.75	2.15	2	2.64	3.39	2.43
Total current liabilities	-13.5%	97	112	98	120	136	94
Total liabilities	-12.7%	207	237	237	265	253	216
Equity share capital	0%	8.51	8.51	8.51	8.51	8.51	8.51
Total equity	4.3%	339	325	313	299	292	275
Total equity and liabilities	-2.9%	546	562	550	564	546	491

Cash Flow for Hester Biosciences

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-38.9%	12	19	8.99	0	-	-
Change in inventories	-49%	5.2	9.23	-9.43	-13.16	-	-
Depreciation	0%	17	17	9.39	17	-	-
Unrealised forex losses/gains	-58%	-0.77	-0.12	0.08	0.78	-	-
Adjustments for interest income	14.3%	2.04	1.91	2.17	1.9	-	-
Net Cashflows from Operations	27.1%	76	60	32	26	-	-
Income taxes paid (refund)	-9.1%	11	12	8.11	17	-	-
Net Cashflows From Operating Activities	36.2%	65	48	24	8.81	-	-
Proceeds from sales of PPE	22.3%	0.27	0.06	0.03	0.18	-	-
Purchase of property, plant and equipment	-13%	21	24	78	96	-	-
Interest received	-119.1%	0.83	1.89	0.51	0.26	-	-
Other inflows (outflows) of cash	57.9%	0.49	-0.21	0.23	-0.51	-	-
Net Cashflows From Investing Activities	15.4%	-19	-22.65	-77	-116.59	-	-
Payments of other equity instruments	-	0	0	0	0.41	-	-
Proceeds from borrowings	-105.3%	0	20	56	135	-	-
Repayments of borrowings	-34.7%	33	50	17	18	-	-
Payments of lease liabilities	1.4%	0.31	0.3	0	0	-	-
Dividends paid	-28.1%	5.17	6.8	8.51	8.51	-	-
Interest paid	-14.3%	13	15	13	2.54	-	-
Other inflows (outflows) of cash	-104%	0	26	24	6.19	-	-
Net Cashflows from Financing Activities	-94.9%	-51.72	-26.05	42	112	-	-
Effect of exchange rate on cash eq.	-79.8%	-0.51	0.16	0.05	-0.35	-	-
Net change in cash and cash eq.	-447.5%	-6.72	-0.41	-11.59	3.48	-	-

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	5.1%	5.09	4.89	6.26	0	-	-
Change in inventories	-10%	10	11	-8.48	-13.72	-	-
Depreciation	-13.7%	8.58	9.78	9.79	9.5	-	-
Unrealised forex losses/gains	-43.7%	-0.61	-0.12	0.08	0.78	-	-
Adjustments for interest income	14.3%	2.04	1.91	2.09	1.9	-	-
Net Cashflows from Operations	37.7%	74	54	41	32	-	-
Income taxes paid (refund)	-10.8%	9.92	11	8.06	16	-	-
Net Cashflows From Operating Activities	50%	64	43	33	16	-	-
Proceeds from sales of PPE	22.3%	0.27	0.06	0.03	0.18	-	-
Purchase of property, plant and equipment	-4.8%	21	22	73	91	-	-
Interest received	-119.1%	0.83	1.89	0.43	0.26	-	-
Other inflows (outflows) of cash	57.9%	0.49	-0.21	0.23	-20.36	-	-
Net Cashflows From Investing Activities	7.4%	-19.04	-20.63	-71.96	-110.58	-	-
Proceeds from borrowings	-105.3%	0	20	52	118	-	-
Repayments of borrowings	-42.9%	29	50	17	13	-	-
Dividends paid	-28.1%	5.17	6.8	8.51	8.51	-	-
Interest paid	0%	13	13	9.87	1.36	-	-
Other inflows (outflows) of cash	-104%	0	26	24	0	-	-
Net Cashflows from Financing Activities	-88.9%	-46.35	-24.07	41	95	-	-
Net change in cash and cash eq.	16.3%	-1.42	-1.89	2.77	0.28	-	-

What does Hester Biosciences Ltd do?

Pharmaceuticals•Healthcare•Small Cap

Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through Poultry Healthcare, Animal Healthcare, and Petcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers livestock vaccines for goat pox, peste des petits ruminants, brucella abortus, contagious bovine pleuropneumonia, CCPP, and lumpy skin diseases; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutic treatment, herbal supplements, homeopathic remedies, and feed supplements. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, coat nutrition, grooming aids, and anti-infective formulations. Additionally, the company provides seroprofiling kits; diagnostic labs for poultry flocks; and mastitis control programs for cattle; as well as engages in manufacturing and trading of goods. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Ahmedabad, India.

Industry Group:Pharmaceuticals & Biotechnology

Employees:642

Website:www.hester.in

HESTERBIO - Hester Biosciences Ltd Share Price

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Risk & Volatility

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Hester Biosciences Ltd do?